Effect of Vonoprazan, a Potassium-Competitive Acid Blocker, on the 13 C-Urea Breath Test in Helicobacter pylori -Positive Patients

Abstract

Background and Aim

Vonoprazan (VPZ) is a new oral potassium-competitive acid blocker that has recently become available. The aim of this study was to investigate the effects of VPZ on the urease activity of H. pylori as measured by the ¹³C-urea breath test (¹³C-UBT).

Patients and Methods

A total of 60 patients (26 men, 34 women; mean age 53.2 ± 13.6 years) who were diagnosed as H. pylori-positive were recruited. The patients were randomly allocated to three treatment groups: lansoprazole (LPZ) 30 mg (n = 20), VPZ 20 mg (n = 20) once daily for 3 weeks, or the control group (n = 20). The ¹³C-UBT was carried out at baseline and after 3 weeks of treatment, and the baseline and after treatment results then compared. Δ¹³C‰ ≥ 2.5‰ was considered H. pylori-positive.

Results

Four patients failed to complete the medication and were omitted from the analysis; data from the LPZ group (n = 18), VPZ group (n = 18), and control group (n = 20) were analyzed. The control group showed no significant change in ¹³C-UBT data between baseline and the completion of 3-week treatment (baseline: 26.6 ± 23.0‰, completion: 21.1 ± 13.1‰). The ¹³C-UBT data at week 3 were significantly decreased in both the VPZ group (baseline: 32.8 ± 22.7‰, completion: 7.6 ± 9.2‰, p = 0.0002) and the LPZ group (baseline: 41.8 ± 33.4‰; completion: 9.6 ± 8.8‰, p = 0.0006) compared to baseline.

Conclusions

VPZ treatment reduced the value of UBT, warning that UBT for patients with VPZ treatment should be evaluated carefully.

from Gastroenterology via xlomafota13 on Inoreader http://ift.tt/2ilMljS
via IFTTT